JP2023505915A5 - - Google Patents
Info
- Publication number
- JP2023505915A5 JP2023505915A5 JP2022554968A JP2022554968A JP2023505915A5 JP 2023505915 A5 JP2023505915 A5 JP 2023505915A5 JP 2022554968 A JP2022554968 A JP 2022554968A JP 2022554968 A JP2022554968 A JP 2022554968A JP 2023505915 A5 JP2023505915 A5 JP 2023505915A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025079712A JP2025120182A (ja) | 2019-11-19 | 2025-05-12 | アデノシン受容体拮抗薬化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190149117A KR20210061202A (ko) | 2019-11-19 | 2019-11-19 | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| KR10-2019-0149117 | 2019-11-19 | ||
| PCT/IB2020/000971 WO2021099838A1 (en) | 2019-11-19 | 2020-11-19 | Adenosine receptor antagonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025079712A Division JP2025120182A (ja) | 2019-11-19 | 2025-05-12 | アデノシン受容体拮抗薬化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023505915A JP2023505915A (ja) | 2023-02-13 |
| JPWO2021099838A5 JPWO2021099838A5 (https=) | 2024-12-04 |
| JP2023505915A5 true JP2023505915A5 (https=) | 2024-12-04 |
| JP7681616B2 JP7681616B2 (ja) | 2025-05-22 |
Family
ID=75980093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554968A Active JP7681616B2 (ja) | 2019-11-19 | 2020-11-19 | アデノシン受容体拮抗薬化合物 |
| JP2025079712A Pending JP2025120182A (ja) | 2019-11-19 | 2025-05-12 | アデノシン受容体拮抗薬化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025079712A Pending JP2025120182A (ja) | 2019-11-19 | 2025-05-12 | アデノシン受容体拮抗薬化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12606564B2 (https=) |
| EP (1) | EP4061817A4 (https=) |
| JP (2) | JP7681616B2 (https=) |
| KR (3) | KR20210061202A (https=) |
| CN (2) | CN116425756B (https=) |
| AU (2) | AU2020386189B2 (https=) |
| BR (2) | BR122023020015A2 (https=) |
| CA (1) | CA3158731A1 (https=) |
| CL (1) | CL2022001307A1 (https=) |
| IL (1) | IL293107A (https=) |
| MX (1) | MX2022005976A (https=) |
| PH (1) | PH12022551223A1 (https=) |
| TW (3) | TWI851336B (https=) |
| WO (3) | WO2021099832A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806350B2 (en) | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| TW202508599A (zh) * | 2023-05-19 | 2025-03-01 | 南韓商尹諾衛醫藥有限公司 | 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| KR20250123663A (ko) | 2024-02-08 | 2025-08-18 | 아이리드비엠에스 주식회사 | Cxcr7 수용체 조절제 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| EP0901476A4 (en) * | 1996-03-26 | 2001-08-16 | Du Pont Pharm Co | PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF |
| PL337888A1 (en) * | 1997-07-03 | 2000-09-11 | Du Pont Pharm Co | Imidazoprimidines and imidazopyridines for use in treating neurological disorders |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100621D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
| DK1444233T3 (da) | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| EP1615926A1 (en) * | 2003-04-21 | 2006-01-18 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (purin-6-yl) amino acid and production method thereof |
| WO2008153947A2 (en) * | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011050160A1 (en) | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
| EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
| DE102017125533A1 (de) | 2017-10-31 | 2019-05-02 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| EP4061798B1 (en) | 2019-11-19 | 2025-03-12 | Clariant International Ltd | Solvates of abscisic acid and liquid compositions containing abscisic acid |
| MX2022005914A (es) | 2019-11-19 | 2022-08-04 | Modag Gmbh | Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina. |
| US11806350B2 (en) * | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
-
2019
- 2019-11-19 KR KR1020190149117A patent/KR20210061202A/ko active Pending
-
2020
- 2020-11-19 KR KR1020247033262A patent/KR102752564B1/ko active Active
- 2020-11-19 CA CA3158731A patent/CA3158731A1/en active Pending
- 2020-11-19 EP EP20890594.3A patent/EP4061817A4/en active Pending
- 2020-11-19 BR BR122023020015-2A patent/BR122023020015A2/pt unknown
- 2020-11-19 TW TW112125972A patent/TWI851336B/zh active
- 2020-11-19 TW TW109140607A patent/TW202132304A/zh unknown
- 2020-11-19 WO PCT/IB2020/000948 patent/WO2021099832A2/en not_active Ceased
- 2020-11-19 WO PCT/IB2020/000971 patent/WO2021099838A1/en not_active Ceased
- 2020-11-19 AU AU2020386189A patent/AU2020386189B2/en active Active
- 2020-11-19 JP JP2022554968A patent/JP7681616B2/ja active Active
- 2020-11-19 TW TW109140608A patent/TWI850492B/zh active
- 2020-11-19 WO PCT/IB2020/000970 patent/WO2021099837A1/en not_active Ceased
- 2020-11-19 MX MX2022005976A patent/MX2022005976A/es unknown
- 2020-11-19 PH PH1/2022/551223A patent/PH12022551223A1/en unknown
- 2020-11-19 CN CN202211456336.XA patent/CN116425756B/zh active Active
- 2020-11-19 CN CN202080080922.1A patent/CN114829363B/zh active Active
- 2020-11-19 BR BR112022009487A patent/BR112022009487A2/pt unknown
- 2020-11-19 IL IL293107A patent/IL293107A/en unknown
- 2020-11-19 US US17/777,881 patent/US12606564B2/en active Active
- 2020-11-19 KR KR1020227020600A patent/KR102749480B1/ko active Active
-
2022
- 2022-05-18 CL CL2022001307A patent/CL2022001307A1/es unknown
-
2023
- 2023-05-09 AU AU2023202886A patent/AU2023202886B2/en active Active
-
2025
- 2025-05-12 JP JP2025079712A patent/JP2025120182A/ja active Pending